DGDominik Gajewski

Dominik Gajewski

*This is an algorithmically generated author record based on publicly available information.

Dominik Gajewski has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond the HPG Axis in Relative Energy Deficiency in Sport: Sleep, Psychological Health, and Neuroendocrine Adaptation in Athletes — A Structured Narrative Review

    by Mateusz Polak, Jakub Grandos, Beata Huszcza, Agnieszka Olejnik, Konrad Gronek, Julia Kaczmarek, Dominik Gajewski, Zuzanna Głowacka, Kinga Kościołek, Mateusz Kosowski

    Background: Relative Energy Deficiency in Sport (REDs) is increasingly viewed as a multisystem condition related to problematic low energy availability (LEA), but evidence beyond reproductive and skeletal outcomes is uneven. Objective: To synthesize evidence on sleep, psychological health and neuroendocrine adaptation in athletes with LEA/REDs, while distinguishing established mechanisms from emerging domains. Methods: A structured narrative review with evidence mapping was conducted in PubMed/MEDLINE; 61 full-text records were assessed and synthesized across predefined domains. Findings: The strongest support concerns endocrine and metabolic adaptation, including thyroid, adipokine, somatotropic and stress-axis pathways, although individual markers remain non-specific. Sleep and psychological outcomes are clinically relevant but rely mainly on heterogeneous, mostly observational evidence. Direct neurocognitive evidence in athletes with well-characterized LEA/REDs remains insufficient. Conclusions: REDs should be considered beyond an HPG-centered framework, but claims regarding sleep, psychological health and neurocognition require caution. Future studies should combine objective LEA characterization, longitudinal designs, endocrine profiling, sleep assessment and direct cognitive testing.

  • Open Access

    Current biological therapies and malignancy risk

    by Adrian Majtas, Zofia Możdżan, Edward Zheng, Agnieszka Olejnik, Dominik Gajewski, Jakub Tambor, Igor Tambor, Agnieszka Nowosielska-Ogórek, Konrad Gronek, Beata Huszcza

    Background. Biological therapies and small-molecule inhibitors have transformed the treatment of chronic inflammatory diseases, though long-term malignancy risks remain a clinical concern. This review evaluates the oncogenic risks of major classes, including TNF-α, interleukin (IL), and Janus kinase (JAK) inhibitors, alongside B-cell depleting agents. While TNF-α and JAK inhibitors may increase certain skin cancers or lymphomas in specific populations, IL-17 and IL-23 inhibitors maintain a favorable safety profile. Paradoxically, controlling chronic inflammation can reduce the risk of inflammation-driven malignancies like colorectal cancer. Aim. To evaluate the malignancy risks of major therapeutic classes (TNF-α, IL, and JAK inhibitors), focusing on clinically significant cancers like HSTCL and skin malignancies, while assessing modifying factors such as age and cumulative exposure. Material and methods. A narrative literature review was conducted using clinical trials, meta-analyses, and observational data from PubMed and the Cochrane Library. Results were synthesized narratively due to study heterogeneity, methodological constraints, and short follow-up periods. Results. TNF-α and JAK inhibitors are associated with an increased risk of non-melanoma skin cancer (NMSC) and certain lymphomas. In contrast, IL-17 and IL-23 inhibitors show safety profiles consistent with baseline population rates. Hepatosplenic T-cell lymphoma (HSTCL) is almost exclusively linked to combination therapy with thiopurines. Effectively neutralizing chronic inflammation can lower the risk of certain cancers, such as colorectal cancer. Conclusions. Biological therapies generally do not increase the risk of solid tumors above baseline. Aggressive oncological risks are typically driven by concomitant therapies (e.g., thiopurines) or the underlying disease itself. Regular dermatological and gynecological screening remains essential to balance therapeutic efficacy with safety.

  • Open Access

    The Role of Physical Activity in Lower Extremity Peripheral Artery Disease.

    by Julia Kaczmarek, Oliwia DziewięCka, Dominik Gajewski, Zuzanna Głowacka, Jakub Grandos, Konrad Gronek, Beata Huszcza, Kinga Kościółek, Agnieszka Olejnik, Edward Zheng, et al.

    Peripheral artery disease (PAD) is a common disorder characterised by a reduced blood circulation caused by stenosis or occlusion of peripheral arteries of the limbs, predominantly affecting the lower extremities. This condition is typically related to atherosclerosis, but it might also be caused by vasculitis, fibromuscular dysplasia, or adventitial cystic disease. Although atherosclerotic occlusive disease of the lower extremities has high mortality and morbidity rates, it remains underdiagnosed and undertreated condition. The risk factors of PAD are similar to those for coronary and cerebrovascular disease. The most common symptom of PAD is intermittent claudication, but recent studies show that asymptomatic PAD is several times more common in the population than intermittent claudication. The medical approach to peripheral artery disease is multifaceted and includes smoking cessation, lipid-lowering therapy, antiplatelet therapy, antithrombotic therapy, peripheral vasodilators, blood pressure management, glycemic control and various methods of revascularization. An important, although frequently neglected aspect is an exercise therapy. Walking exercise is first-line therapy for PAD-related walking impairment. Supervised walking exercise and structured home-based walking exercise each not only improve walking ability, but also have other benefits, which we would like to discuss in this review.

  • Open Access

    Genetic Determinants of Inter-Individual Variability in Statin Therapy

    by Agnieszka Olejnik, Edward Zheng, Maria Możdżan, Laura Biskup, Beata Huszcza, Konrad Gronek, Julia Kaczmarek, Jakub Grandos, Dominik Gajewski, Zuzanna Głowacka, et al.

    Statins, or HMG-CoA reductase inhibitors, represent one of the most extensively researched and frequently prescribed pharmacological agents, primarily utilized to reduce cardiovascular risk through the modulation of serum cholesterol levels. Although their efficacy in reducing global mortality and cardiovascular events is well-established, genetic variability persists among different populations which may predispose patients to dose-related adverse effects and reduced efficancy of statin therapy. This heterogeneity has driven a shift in the scientific landscape toward exploring common genetic polymorphisms within the genes encoding genes involved in pharmacodynamic pathways. This review aims to provide a comprehensive analysis of clinically significant polymorphisms within the pharmacodynamic pathways of statins. Methods: A systematic literature review was conducted in accordance with PRISMA guidelines. Databases including PubMed, Embase, and the Cochrane Library were searched for peer-reviewed publications from 2021 to 2025. Following a rigorous selection process based on Evidence-Based Medicine (EBM) criteria. Conclusions: Despite rapid progress in the field of pharmacogenomics, the role of genetic polymorphisms among genes involved in pharmacodynamic pathways of statin therapy still requires more research in order to establish robust evidence of their role in the overall lipid-lowering efficacy of statins.

  • Open Access

    THE EVOLUTION OF AI MEDICAL CONSULTANTS AND THEIR IMPACT ON PATIENT EDUCATION: A LITERATURE REVIEW

    by Agnieszka Olejnik, Maria Możdżan, Laura Biskup, Edward Zheng, Beata Huszcza, Konrad Gronek, Julia Kaczmarek, Jakub Grandos, Dominik Gajewski, Zuzanna Głowacka, et al.

    Background: The rapid development of Artificial Intelligence (AI) has led to its transition from a theoretical concept in informatics to a functional clinical tool. This study evaluates the impact of AI-based consultants and Large Language Models (LLMs) on patient health literacy and the quality of medical education within the framework of contemporary healthcare standards. Methods: A systematic literature review was conducted in accordance with PRISMA guidelines. Databases including PubMed, Embase, and the Cochrane Library were searched for peer-reviewed publications from 2021 to 2025. Following a rigorous selection process based on Evidence-Based Medicine (EBM) criteria, 31 key sources were identified and synthesized. Results: LLMs significantly improve the comprehensibility of clinical terminology by adapting medical content to a 9th-11th-grade literacy level. Digital feedback systems, such as the KidneyOnline platform, demonstrate superior efficacy in improving patient adherence compared with standard protocols. However, several critical limitations were identified, including hallucination bias (fabrication of clinical data), a “readability floor” phenomenon associated with up to 83% content reduction, and the risk of professional deskilling among clinicians. Furthermore, wearable devices such as the Apple Watch show high correlation (r=0.92) with medical-grade pulse oximetry, offering new perspectives for real-time health monitoring. Conclusions: AI represents a transformative yet socially consequential innovation in patient education and health literacy. Its responsible implementation requires a strict human-in-the-loop model to ensure clinical safety, ethical accountability, and equitable access. Systematic verification of AI-generated medical information by qualified healthcare professionals remains essential to maintain both high standards of care and public trust in digital health innovations.

  • Open Access

    Antidepressant Pharmacotherapy and Structured Physical Activity in Major Depressive Disorder: Implications for Functional Capacity and Cardiometabolic Health

    by Konrad Gronek, Edward Zheng, Agnieszka Olejnik, Maria Możdżan, Laura Biskup, Beata Huszcza, Julia Kaczmarek, Jakub Grandos, Dominik Gajewski, Zuzanna Głowacka, et al.

    Major depressive disorder (MDD) is a multidimensional condition associated not only with affective symptoms but also with reduced physical activity, impaired functional capacity, and increased cardiometabolic risk. Beyond mood disturbance, depression is frequently accompanied by decreased cardiorespiratory fitness, altered body composition, and autonomic dysregulation. While antidepressant pharmacotherapy remains a cornerstone of treatment, structured physical activity has emerged as a clinically relevant intervention within sports and lifestyle medicine. Evidence from recent meta-analyses and network meta-analyses demonstrates moderate antidepressant effects of aerobic and resistance-based exercise interventions. Comparative analyses suggest similar efficacy of exercise and pharmacotherapy in mild-to-moderate depression, with structured training providing additional benefits for cardiovascular performance, metabolic regulation, and functional recovery. The bidirectional relationship between depression and metabolic syndrome further underscores the importance of addressing systemic risk factors alongside psychiatric symptoms. Antidepressant agents differ in their metabolic, autonomic, and endocrine profiles, with potential implications for weight regulation, insulin sensitivity, and exercise adherence. Overlapping biological mechanisms between pharmacotherapy and physical training include monoaminergic modulation, neuroplasticity enhancement through brain-derived neurotrophic factor pathways, and attenuation of systemic inflammation. However, direct randomized comparisons of combined pharmacotherapy and structured exercise remain limited. An individualized treatment model integrating pharmacological stabilization with progressive physical training may optimize both psychological recovery and longterm physiological resilience in patients with major depressive disorder.